Correlative studies of immune function in patients who received CTL infusion. Data for 37 patients for whom results were available. (A) Peak IFN-γ EliSpot for pp65 (CMV) and adenovirus hexon protein postinfusion of T cells. Counts displayed are the maximum measured for each patient above negative control. Bars represent medians, boxes represent 25th to 75th percentiles, and whiskers represent the 10th and 90th percentiles. Individual results outside these parameters are shown (●). (B) Peak pp65-specific immunity as measured by IFN-γ EliSpot in recipients of CTL who did and did not develop CMV reactivation. Bars represent medians, boxes represent 25th to 75th percentiles, and whiskers represent the 10th and 90th percentiles. Individual results outside these parameters are shown (●). (C-D) CMV-specific immunity over time in recipients of CTL who did (C, n = 19) and did not (D, n = 18) develop CMV reactivation at any time posttransplant. PBMC collected at preinfusion and follow-up time points were incubated with pp65 peptide mix in an IFN-γ EliSpot immunoassay. Results are expressed as spot-forming units/105 cells above negative control. (E-G) Representative examples of CMV pp65-specific immunity and adenovirus hexon-specific immunity as measured by IFN-γ EliSpot in 3 recipients of CMV CTL who developed CMV reactivation. (E, patient 40; F, patient 20; G, patient 25). (H-J) Representative examples of CMV pp65-specific immunity and adenovirus hexon-specific immunity as measured by IFN-γ EliSpot in 3 recipients of CMV CTL who did not develop CMV reactivation. (H, patient 26; I, patient 17; J, patient 44).
